BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 12898186)

  • 21. Late appearance of Philadelphia chromosome with the p190 BCR/ABL chimeric transcript in acute myelogenous leukemia progressing from myelodysplastic syndrome.
    Kakihana K; Mizuchi D; Yamaguchi M; Sakashita C; Fukuda T; Yamamoto K; Miki T; Murakami N; Miura O
    Rinsho Ketsueki; 2003 Apr; 44(4):242-8. PubMed ID: 12784657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Philadelphia chromosome positive myelodysplastic syndrome and acute myelogenous leukemia.
    Advani AS
    Leuk Res; 2004 Jun; 28(6):545-6. PubMed ID: 15120928
    [No Abstract]   [Full Text] [Related]  

  • 23. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
    Zámecníkova A; Al Bahar S; Ramesh P
    Leuk Res; 2008 Sep; 32(9):1454-7. PubMed ID: 18294688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Deletion (7)(p11p15): an infrequent abnormality in blast crisis in chronic myeloid leukemia].
    Resino M; Ferro MT; García-Laraña J; García-Sagredo JM; Cabello P; López-Yarto A; San Román C
    Sangre (Barc); 1994 Dec; 39(6):465-7. PubMed ID: 7855700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Blast crisis accompanied by severe DIC of Ph negative chronic myeloid leukemia showing t(9;16) and positive M-BCR/ABL rearrangement].
    Fujiwara H; Takahashi N; Tada J; Higuchi T; Harada H; Mori H; Niikura H; Omine M; Fujita K
    Rinsho Ketsueki; 1997 Aug; 38(8):663-68. PubMed ID: 9311272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosome 20q deletion: a recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission.
    Sun J; Yin CC; Cui W; Chen SS; Medeiros LJ; Lu G
    Am J Clin Pathol; 2011 Mar; 135(3):391-7. PubMed ID: 21350093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
    Agirre X; Román-Gómez J; Vázquez I; Jiménez-Velasco A; Larráyoz MJ; Lahortiga I; Andreu EJ; Márquez J; Beltrán de Heredia JM; Odero MD; Prósper F; Calasanz MJ
    Cancer Genet Cytogenet; 2005 Jul; 160(1):22-6. PubMed ID: 15949566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
    Avery S; Nadal E; Marin D; Olavarria E; Kaeda J; Vulliamy T; Brito Babapulle F; Goldman JM; Apperley JF
    Leuk Res; 2004 May; 28 Suppl 1():S75-7. PubMed ID: 15036946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic myeloid leukemia with a rare variant BCR-ABL translocation: t(9;22;21)(q34;q11.2;q11.2).
    Takeuchi M; Katayama Y; Okamura A; Yamamoto K; Shimoyama M; Matsui T
    Cancer Genet Cytogenet; 2007 Nov; 179(1):85-7. PubMed ID: 17981222
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
    Ahmed MS; Kroft SH; Davis NB; King DM; Cheng YC
    Leuk Res; 2008 Sep; 32(9):1476-9. PubMed ID: 18308388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
    Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
    Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia.
    Colla S; Sammarelli G; Crugnola M; Ascani S; Sabbatini E; Bonomini S; Hojden M; Craviotto L; De Celis I; Morandi F; Caramatti C; Rizzoli V; Giuliani N
    Eur J Haematol; 2004 May; 72(5):361-5. PubMed ID: 15059073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate.
    Kubota Y; Waki M
    Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400
    [No Abstract]   [Full Text] [Related]  

  • 37. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
    Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
    Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
    Morita R; Hashino S; Sogabe S; Dazai M; Onozawa M; Izumiyama K; Kondo T; Ota S; Kobayashi S; Imamura M; Asaka M
    Rinsho Ketsueki; 2004 Oct; 45(10):1105-10. PubMed ID: 15553045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.